Contact PR

To use this feature, join Babbler easily !

Nice to see you again !

Download this content

Fill in this form and allow the PR contact who posted this content to identify you.

Invalid email address
Press release

SOTAGLIFLOZIN
timer minutes reading time minute reading time

Copy link
CURRENTLY IN REGULATORY REVIEW IN THE EU AND U.S. FOR USE AS AN ADJUNCT TO INSULIN THERAPY TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 1 DIABETES
sotagliflozin

Click to get original image size

Sotagliflozin is the first investigational, oral SGLT-1/2 dual inhibitor in clinical development for Type 1 Diabetes (T1D)

  • Health & Medicine
  • Medicine
  • Men's Health
  • Women's Health